Brief: Inovio Announces U.S. FDA Breakthrough Therapy Designation Granted For Ino-3107 For The Treatment Of Recurrent Respiratory Papillomatosis
07/09/2023 15:09
Inovio Pharmaceuticals Inc INO.O :
* INOVIO ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION
GRANTED FOR INO-3107 FOR THE TREATMENT OF RECURRENT RESPIRATORY
PAPILLOMATOSIS
* INOVIO PHARMACEUTICALS INC - PLANS TO INITIATE A PIVOTAL
TRIAL
OF INO-3107 IN Q1 OF 2024
Source text for Eikon: ID:nPn9WJ0qLa
Further company coverage: INO.O
Recent news on Inovio Pharmaceuticals
See all newsBrief: Inovio Announces Favorable Judgment In Litigation With Vgxi, Inc. And Geneone Life Science
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Inovio Q2 net loss narrows on warrant gain, lower costs
Brief: Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million